Join the Pancreatic Cancer group to help and get support from people like you.
Pancreatic Cancer News (Page 2)
Related terms: Cancer, Pancreas, Cancer, Pancreatic, Pancreatic Carcinoma
AI-Assisted Model Improves Diagnosis of Solid Lesions in Pancreas
MONDAY, July 22, 2024 – A joint artificial intelligence (AI)-assisted model integrating clinical information and endoscopic ultrasonographic (EUS) images improves diagnosis of solid lesions in the...
Scientists Find Way to Reverse Chemo Resistance in Pancreatic Cancer Patients
MONDAY, July 8, 2024 – Pancreatic cancer is particularly aggressive and difficult to treat, partly because it’s often resistant to chemotherapy. Researchers now think they know why chemo struggles t...
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 – For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant modified 5-fluorouracil,...
Timing of Chemo Could Be Key to Pancreatic Cancer Outcomes
MONDAY, June 24, 2024 – Giving people with pancreatic cancer chemotherapy both before and after a tumor-removing surgery brought better outcomes than if they got the drugs only after the surgery,...
Most Cancer Treatments Near End of Life Are Useless: Study
FRIDAY, May 17, 2024 – Cutting-edge cancer treatments are essentially useless for patients barely clinging to life, a new study shows. Chemotherapies, immunotherapies, targeted therapies and hormone...
Ipsen’s Onivyde Regimen, a Potential New Standard-of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
PARIS, FRANCE, 13 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde (...
Lynparza (olaparib) Approved in the US as a First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
30 December 2019 – AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that Lynparza® (olaparib) has been approved in the US for ...
FDA Approves Onivyde (irinotecan liposome injection) for Advanced Pancreatic Cancer
October 22, 2015 – The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced...
FDA Approves Abraxane for Late-Stage Pancreatic Cancer
September 6, 2013 – The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients...
FDA Approves Sutent for Rare Type of Pancreatic Cancer
SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors...
Novartis Gains FDA Approval for Afinitor As First New Treatment in Nearly Three Decades for Patients With Advanced Pancreatic NET
Basel, May 5, 2011 - Novartis announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of progressive neuroendocrine tumors of...